by Heparin calcium is a widely used anticoagulant produced from mammalian tissues. It is commonly used to prevent and treat blood clots in conditions such as deep vein thrombosis and pulmonary embolism. Heparin calcium injections are also administered during surgical procedures and kidney dialysis to prevent coagulation. The global heparin calcium market comprises products such as injectables and oral formulations used across applications in thrombosis and cardiovascular diseases. Rising geriatric population is a key driver as the prevalence of blood clotting issues increases with age. It is estimated that by 2050 over 16% of the world’s population will be aged 65 years and above. The growing elderly base prone to thrombotic disorders and cardiac problems is heightening the demand for anticoagulants like heparin calcium.
The global Heparin Calcium Market is estimated to be valued at US$ 1407.91 million in 2023 and is expected to exhibit a CAGR of 2.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics
The rising geriatric population as mentioned in the heading is one of the key drivers propelling the growth of the global heparin calcium market. As per the UN’s World Population Ageing Report, between 2020 and 2050, the number of people aged 65 years or over is projected to grow by 12% annually. By 2050, one in six people in the world will be aged over 65, up from one in 11 in 2019. Elderly individuals are more prone to thromboembolic conditions necessitating long-term anticoagulation therapy.
This growing pool of seniors globally will consistently augment demand for heparin calcium. Another driver is the increasing incidence of cardiovascular diseases including cardiac arrhythmia, heart failure, and myocardial infarction where heparin calcium can be therapeutically applied. As per the WHO, cardiovascular diseases account for over 17 million deaths each year which is estimated to grow to over 23.6 million by 2030. The rising burden of cardiac ailments worldwide will propel uptake of heparin calcium for anticoagulation during procedures and management of associated conditions.
Segment Analysis
The Heparin Calcium market can be segmented into pharmaceutical grade heparin calcium and food grade heparin calcium. Pharmaceutical grade heparin calcium dominates the market and holds around 85% share owing to its widespread application as an anticoagulant during surgeries and dialysis. It prevents the formation of clots in blood and plasma during these medical procedures.
PEST Analysis
Political: The heparin calcium market is regulated under stringent medical policies and safety guidelines issued by regulatory bodies like FDA to ensure quality and efficacy of the drug. Any non-compliance can affect the sales and revenue of companies.
Economic: Rising healthcare spending on critical illness, surgeries and dialysis is driving the demand for anticoagulants like heparin calcium. Additionally, growth in geriatric population prone to coagulation disorders fuels the market growth.
Social: The increasing prevalence of lifestyle diseases, cardiovascular problems and cases of blood clots due to sedentary habits, obesity etc. have boosted the need for anticoagulants in recent times. This acts as a key social driver for heparin calcium consumption.
Technological: Advancements in production technologies help manufacturers enhance yields and optimize costs. Research in drug delivery systems can also help increase the bioavailability and efficacy of heparin calcium formulations.
Key Takeaways
The global Heparin Calcium Market Size is expected to witness high growth on account of aging population, rising chronic illnesses and increasing surgical procedures worldwide. Regionally, North America commands the major share of over 35% in the global market owing to developed healthcare infrastructure and growing disease burden. Europe and Asia Pacific also offer lucrative opportunities for market players.
Key players operating in the heparin calcium market are Sanofi, Pfizer Inc., Dongying Tiandong Pharmaceutical Co., Ltd., PANPHARMA S.A., Merck KGaA, Teva Pharmaceutical Industries Ltd., SMITHFIELD BIOSCIENCE, Afine Chemicals Limited, Yino Pharma Limited, Shandong Sheelian Pharmaceutical Co., Ltd. and Aspen Holdings, Opocrin S.p.A. Sanofi leads the market with over 20% share due to its strong brand presence and diverse product portfolio in the anticoagulant segment.
Regional analysis
Regional analysis comprises North America holds the major share of over 35% of heparin calcium market owing to well-established healthcare system and infrastructure along with presence of advanced medical facilities. Growing geriatric population and increased prevalence of chronic diseases have also augmented the demand in the region. Europe is another major regional market driven by supportive government policies and healthcare investment. Asia Pacific region is expected to witness fastest growth during the forecast period. Rising medical tourism, increasing healthcare expenses, growing middle class population and economic development offer lucrative opportunities for market expansion in Asia Pacific.
Key players
Key players operating in the heparin calcium market are Sanofi, Pfizer Inc., Dongying Tiandong Pharmaceutical Co., Ltd., PANPHARMA S.A., Merck KGaA, Teva Pharmaceutical Industries Ltd., SMITHFIELD BIOSCIENCE, Afine Chemicals Limited, Yino Pharma Limited, Shandong Sheelian Pharmaceutical Co., Ltd. and Aspen Holdings, Opocrin S.p.A. Sanofi leads the market with over 20% share due to its strong brand presence and diverse product portfolio in the anticoagulant segment.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
